

1. (Currently Amended) ~~A method of~~ Use of pomalidomide in the manufacture of a medicament for treating, preventing, or managing one or more symptoms of hematological cancer in a subject with renal impairment, ~~comprising administering to the subject a therapeutically~~ wherein the medicament is for administration in combination with a second therapeutic agent in a subtherapeutically effective amount of pomalidomide, wherein the therapeutically effective amount is an amount lower than the amount administered to a patient without renal impairment.

2. (Cancelled) ~~The method of claim 1, wherein the cancer is hematological cancer.~~

2 ~~[[3]].~~ (Currently Amended) ~~The method use of claim 1~~ [[2]], wherein the hematological cancer is multiple myeloma.

3 ~~[[4]].~~ (Currently Amended) ~~The method use of claim 1 or 2 any of claims 1 to 3,~~ wherein the hematological cancer is drug-resistant.

4 ~~[[5]].~~ (Currently Amended) ~~The method use of any of claims 1 to ]]~~ 34]], wherein the hematological cancer is relapsed or refractory.

5 ~~[[6]].~~ (Currently Amended) ~~The method use of any of claims 1 to 4]]~~ 5]], wherein the therapeutically effective amount medicament is for administration of pomalidomide is in the range in an amount ranging from about 1 mg to about 50 mg per day.

6 ~~[[7]].~~ (Currently Amended) ~~The method use of claim ]]~~ 56]], wherein the therapeutically effective amount medicament is for administration of pomalidomide is in the range in an amount ranging from about 2 mg to about 25 mg per day.

7 ~~[[8]].~~ (Currently Amended) ~~The method use of claim ]]~~ 56]], wherein the therapeutically effective amount medicament is for administration of pomalidomide is in the range in an amount ranging from about 2 mg to about 15 mg per day.

8 ~~[[9]].~~ (Currently Amended) ~~The method use of claim ]]~~ 56]], wherein the therapeutically effective amount medicament is for administration of pomalidomide is in an amount of about 2 mg, about 4 mg, or about 6 mg per day.

9 [[10]]. (Currently Amended) The ~~method~~ use of claim ]] 56]], wherein the ~~therapeutically effective amount~~ medicament is for administration of pomalidomide is in an amount of about 2 mg per day.

10 [[11]]. (Currently Amended) The ~~method~~ use of claim ]] 56]], wherein the ~~therapeutically effective amount~~ medicament is for administration of pomalidomide is in an amount of about 4 mg per day.

11 [[12]]. (Currently Amended) The ~~method~~ use of any of claims 1 to 10 [[11]], wherein the medicament is for administration of pomalidomide is administered once a day.

12 [[13]]. (Currently Amended) The ~~method~~ use of any of claims 1 to 11 [[12]], wherein the medicament is for administration of pomalidomide is administered for 21 days in a 28 day treatment cycle.

13 [[14]]. (Currently Amended) The ~~method~~ use of claim 12 [[13]], wherein the medicament is for administration of pomalidomide is administered daily on days 1 to 21 in the 28 day treatment cycle.

14 [[15]]. (Currently Amended) The ~~method~~ use of any of claims 1 to 13 [[14]], wherein the medicament is for oral administration of pomalidomide is administered orally.

15 [[16]]. (Currently Amended) The ~~method~~ use of any of claims 1 to 14 [[15]], wherein the subject has creatinine clearance of no greater than about 80 mL/min.

16 [[17]]. (Currently Amended) The ~~method~~ use of claim ]] 1516]], wherein the subject has mild renal impairment.

17 [[18]]. (Currently Amended) The ~~method~~ use of claim ]] 1516]], wherein the subject has moderate renal impairment.

18 [[19]]. (Currently Amended) The ~~method~~ use of claim ]] 1516]], wherein the subject has severe renal impairment.

19 [[20]]. (Currently Amended) The ~~method~~ use of any of claims 1 to 18 [[19]], wherein the subject is a human.

20 [[21]]. (Currently Amended) The ~~method~~ use of claim 5, wherein the medicament is for administration of pomalidomide in an amount of about 1 mg per day ~~any of claims 1 to 20, further comprising administering to the subject a second therapeutic agent.~~

21 [[22]]. (Currently Amended) The ~~method~~ use of claim 5 [[21]], wherein the medicament is for administration of pomalidomide in an amount of about 3 mg per day ~~second therapeutic agent is administered in a subtherapeutically effective amount.~~

22 [[23]]. (Currently Amended) The ~~method~~ use of claim 21 or 22 any of claims 1 to 21, wherein the second therapeutic agent is dexamethasone.

24. (Cancelled) ~~The method of claim 23, wherein dexamethasone is administered in a subtherapeutically effective amount.~~

23 [[25]]. (Currently Amended) The ~~method~~ use of claim 23 or 24 22, wherein the subtherapeutically effective amount of dexamethasone is administered in the amount ranging from about 10 mg to about 100 mg per week.

24 [[26]]. (Currently Amended) The ~~method~~ use of claim 23 [[25]], wherein the subtherapeutically effective amount of dexamethasone is administered in the amount ranging from about 10 mg to about 50 mg per week.

25 [[27]]. (Currently Amended) The ~~method~~ use of claim 23 [[25]], wherein the subtherapeutically effective amount of dexamethasone is administered in the about 20 mg or about 40 mg per week.

26 [[28]]. (Currently Amended) The ~~method~~ use of claim 23 [[25]], wherein the subtherapeutically effective amount of dexamethasone is administered in the amount of about 20 mg per week.

27 [[29]]. (Currently Amended) The ~~method~~ use of claim 23 [[25]], wherein the subtherapeutically effective amount of dexamethasone is administered in the amount of about 40 mg per week.

28 [[30]]. (Currently Amended) The ~~method~~ use of any of claims 22 to 27 ~~23 to 29~~, wherein dexamethasone is ~~administered~~ for administration once a day.

29 [[31]]. (Currently Amended) The ~~method~~ use of any of claims 22 to 28 ~~23 to 30~~, wherein dexamethasone is ~~administered~~ for administration for 4 days in a 28 day treatment cycle.

30 [[32]]. (Currently Amended) The ~~method~~ use of claim 29 [[31]], wherein dexamethasone is ~~administered~~ for daily administration on days 1, 8, 15, and 22 in the 28 day treatment cycle.

31 [[33]]. (Currently Amended) The ~~method~~ use of any of claims 22 to 28 ~~23 to 30~~, wherein dexamethasone is ~~administered~~ for administration for 12 days in a 28 day treatment cycle.

32 [[34]]. (Currently Amended) The ~~method~~ use of claim 31 [[33]], wherein dexamethasone is ~~administered~~ for daily administration on days 1 to 4, 9 to 12, and 17 to 20 in the 28 day treatment cycle.

33 [[35]]. (Currently Amended) The ~~method~~ use of any of claims 22 to 32 ~~23 to 34~~, wherein dexamethasone is ~~administered orally~~ for oral administration.

34 [[36]]. (Currently Amended) The ~~method~~ use of any of claims 22 to 33 ~~23 to 35~~, wherein the medicament is for administration of pomalidomide is ~~administered~~ before dexamethasone.

35 [[37]]. (Currently Amended) The ~~method~~ use of any of claims 22 to 33 ~~23 to 35~~, wherein the medicament is for administration of pomalidomide is ~~administered~~ concurrently with dexamethasone.

36 [[38]]. (Currently Amended) The ~~method~~ use of any of claims 22 to 33 ~~23 to 35~~, wherein the medicament is for administration of pomalidomide is ~~administered~~ after dexamethasone.

37 [[39]]. (Currently Amended) The ~~method~~ use of any of claims 1 to 36 ~~21 to 38~~, ~~further comprising administering to the subject~~ wherein the medicament is for administration in combination with a third therapeutic agent.

38 [[40]]. (Currently Amended) The ~~method~~ use of any of claims 1 to 37 [[39]], wherein the subject has not been treated with anticancer therapy for the cancer prior to the administration of ~~pomalidomide~~ the medicament.

39 [[41]]. (Currently Amended) The ~~method~~ use of any of claims 1 to 37 [[39]], wherein the subject has been treated with anticancer therapy for the cancer prior to the administration of ~~pomalidomide~~ the medicament.

40 [[42]]. (Currently Amended) The ~~method~~ use of claim 39 [[41]], wherein the subject has been treated with at least two therapies for the cancer prior to the administration of ~~pomalidomide~~ the medicament.

41 [[43]]. (Currently Amended) The ~~method~~ use of claim 39 [[41]], wherein the subject has been treated with lenalidomide or bortezomib for the cancer prior to the administration of ~~pomalidomide~~ the medicament.

42 [[44]]. (Currently Amended) The ~~method~~ use of claim 39 [[41]], wherein the subject has been treated with lenalidomide and bortezomib for the cancer prior to the administration of ~~pomalidomide~~ the medicament.

43 [[45]]. (Currently Amended) ~~A method of~~ Use of pomalidomide in the manufacture of a medicament for inhibiting the growth of a multiple myeloma cell, comprising contacting the cell with pomalidomide and wherein the medicament is to contact with the cell in combination with a subtherapeutically effective amount of dexamethasone.

44 [[46]]. (Currently Amended) The ~~method~~ use of claim 43 [[45]], wherein ~~pomalidomide is contacted with~~ the medicament is to contact the multiple myeloma cell before [[the]] dexamethasone.

45 [[47]]. (Currently Amended) The ~~method~~ use of claim 43 [[45]], wherein ~~pomalidomide is contacted with~~ the medicament is to contact the multiple myeloma cell concurrently with dexamethasone.

46 [[48]]. (Currently Amended) The ~~method~~ use of claim 43 [[45]], wherein ~~pomalidomide is contacted with~~ the medicament is to contact the multiple myeloma cell after dexamethasone.

49. (Cancelled) ~~The method of any of claims 45 to 48, wherein the cell is a cancerous cell.~~

50. (Cancelled) ~~The method of claim 49, wherein the cancerous cell is a cell of bladder cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, gastric cancer, glioma, head and neck cancer, liver cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, or prostate cancer.~~

What is claimed is:

1. A method of treating, preventing, or managing one or more symptoms of cancer in a subject with renal impairment, comprising administering to the subject a therapeutically effective amount of pomalidomide, wherein the therapeutically effective amount is an amount lower than the amount administered to a patient without renal impairment.
2. The method of claim 1, wherein the cancer is hematological cancer.
3. The method of claim 2, wherein the cancer is multiple myeloma.
4. The method of any of claims 1 to 3, wherein the cancer is drug-resistant.
5. The method of any of claims 1 to 4, wherein the cancer is relapsed or refractory.
6. The method of any of claims 1 to 5, wherein the therapeutically effective amount of pomalidomide is in the range from about 1 mg to about 50 mg per day.
7. The method of claim 6, wherein the therapeutically effective amount of pomalidomide is in the range from about 2 mg to about 25 mg per day.
8. The method of claim 6, wherein the therapeutically effective amount of pomalidomide is in the range from about 2 mg to about 15 mg per day.
9. The method of claim 6, wherein the therapeutically effective amount of pomalidomide is about 2, about 4, or about 6 mg per day.
10. The method of claim 6, wherein the therapeutically effective amount of pomalidomide is about 2 mg per day.
11. The method of claim 6, wherein the therapeutically effective amount of pomalidomide is about 4 mg per day.
12. The method of any of claims 1 to 11, wherein pomalidomide is administered once a day.

13. The method of any of claims 1 to 12, wherein pomalidomide is administered for 21 days in a 28 day treatment cycle.

14. The method of claim 13, wherein pomalidomide is administered daily on days 1 to 21 in the 28 day treatment cycle.

15. The method of any of claims 1 to 14, wherein pomalidomide is administered orally.

16. The method of any of claims 1 to 15, wherein the subject has creatinine clearance of no greater than about 80 mL/min.

17. The method of claim 16, wherein the subject has mild renal impairment.

18. The method of claim 16, wherein the subject has moderate renal impairment.

19. The method of claim 16, wherein the subject has severe renal impairment.

20. The method of any of claims 1 to 19, wherein the subject is a human.

21. The method of any of claims 1 to 20, further comprising administering to the subject a second therapeutic agent.

22. The method of claim 21, wherein the second therapeutic agent is administered in a subtherapeutically effective amount.

23. The method of claim 21 or 22, wherein the second therapeutic agent is dexamethasone.

24. The method of claim 23, wherein dexamethasone is administered in a subtherapeutically effective amount.

25. The method of claim 23 or 24, wherein dexamethasone is administered in the amount ranging from about 10 to about 100 mg per week.

26. The method of claim 25, wherein dexamethasone is administered in the amount ranging from about 10 to about 50 mg per week.

27. The method of claim 25, wherein dexamethasone is administered in the amount of about 20 or about 40 mg per week.

28. The method of claim 25, wherein dexamethasone is administered in the amount of about 20 mg per week.

29. The method of claim 25, wherein dexamethasone is administered in the amount of about 40 mg per week.

30. The method of any of claims 23 to 29, wherein dexamethasone is administered once a day.

31. The method of any of claims 23 to 30, wherein dexamethasone is administered for 4 days in a 28 day treatment cycle.

32. The method of claim 31, wherein dexamethasone is administered daily on days 1, 8, 15, and 22 in the 28 day treatment cycle.

33. The method of any of claims 23 to 30, wherein dexamethasone is administered for 12 days in a 28 day treatment cycle.

34. The method of claim 33, wherein dexamethasone is administered daily on days 1 to 4, 9 to 12, and 17 to 20 in the 28 day treatment cycle.

35. The method of any of claims 23 to 34, wherein dexamethasone is administered orally.

36. The method of any of claims 23 to 35, wherein pomalidomide is administered before dexamethasone.

37. The method of any of claims 23 to 35, wherein pomalidomide is administered concurrently with dexamethasone.

38. The method of any of claims 23 to 35, wherein pomalidomide is administered after dexamethasone.

39. The method of any of claims 21 to 38, further comprising administering to the subject a third therapeutic agent.

40. The method of any of claims 1 to 39, wherein the subject has not been treated with anticancer therapy for the cancer prior to the administration of pomalidomide.

41. The method of any of claims 1 to 39, wherein the subject has been treated with anticancer therapy for the cancer prior to the administration of pomalidomide.

42. The method of claim 41, wherein the subject has been treated with at least two therapies for the cancer prior to the administration of pomalidomide.

43. The method of claim 41, wherein the subject has been treated with lenalidomide or bortezomib for the cancer prior to the administration of pomalidomide.

44. The method of claim 41, wherein the subject has been treated with lenalidomide and bortezomib for the cancer prior to the administration of pomalidomide.

45. A method of inhibiting the growth of a cell, comprising contacting the cell with pomalidomide and dexamethasone.

46. The method of claim 45, wherein pomalidomide is contacted with the cell before the dexamethasone.

47. The method of claim 45, wherein pomalidomide is contacted with the cell concurrently with dexamethasone.

48. The method of claim 45, wherein pomalidomide is contacted with the cell after dexamethasone.

49. The method of any of claims 45 to 48, wherein the cell is a cancerous cell.

50. The method of claim 49, wherein the cancerous cell is a cell of bladder cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, gastric cancer, glioma, head and neck cancer, liver cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, or prostate cancer.

What is claimed is:

1. Use of pomalidomide in the manufacture of a medicament for treating, preventing, or managing one or more symptoms of hematological cancer in a subject with renal impairment, wherein the medicament is for administration in combination with a second therapeutic agent in a subtherapeutically effective amount.
2. The use of claim 1, wherein the hematological cancer is multiple myeloma.
3. The use of claim 1 or 2, wherein the hematological cancer is drug-resistant.
4. The use of any of claims 1 to 3, wherein the hematological cancer is relapsed or refractory.
5. The use of any of claims 1 to 4, wherein the medicament is for administration of pomalidomide in an amount ranging from about 1 mg to about 50 mg per day.
6. The use of claim 5, wherein the medicament is for administration of pomalidomide in an amount ranging from about 2 mg to about 25 mg per day.
7. The use of claim 5, wherein the medicament is for administration of pomalidomide in an amount ranging from about 2 mg to about 15 mg per day.
8. The use of claim 5, wherein the medicament is for administration of pomalidomide ~~is~~ in an amount of about 2 mg, about 4 mg, or about 6 mg per day.
9. The use of claim 5, wherein the medicament is for administration of pomalidomide ~~is~~ in an amount of about 2 mg per day.
10. The use of claim 5, wherein the medicament is for administration of pomalidomide ~~is~~ in an amount of about 4 mg per day.
11. The use of any of claims 1 to 10, wherein the medicament is for administration of pomalidomide once a day.
12. The use of any of claims 1 to 11, wherein the medicament is for administration of pomalidomide for 21 days in a 28 day treatment cycle.

13. The use of claim 12, wherein the medicament is for administration of pomalidomide daily on days 1 to 21 in the 28 day treatment cycle.
14. The use of any of claims 1 to 13, wherein the medicament is for oral administration of pomalidomide.
15. The use of any of claims 1 to 14, wherein the subject has creatinine clearance of no greater than about 80 mL/min.
16. The use of claim 15, wherein the subject has mild renal impairment.
17. The use of claim 15, wherein the subject has moderate renal impairment.
18. The use of claim 15, wherein the subject has severe renal impairment.
19. The use of any of claims 1 to 18, wherein the subject is a human.
20. The use of claim 5, wherein the medicament is for administration of pomalidomide in an amount of about 1 mg per day.
21. The use of claim 5, wherein the medicament is for administration of pomalidomide in an amount of about 3 mg per day.
22. The use of any of claims 1 to 21, wherein the second therapeutic agent is dexamethasone.
23. The use of claim 22, wherein the subtherapeutically effective amount of dexamethasone is ranging from about 10 mg to about 100 mg per week.
24. The use of claim 23, wherein the subtherapeutically effective amount of dexamethasone is ranging from about 10 mg to about 50 mg per week.
25. The use of claim 23, wherein the subtherapeutically effective amount of dexamethasone is about 20 mg or about 40 mg per week.
26. The use of claim 23, wherein the subtherapeutically effective amount of dexamethasone is about 20 mg per week.

27. The use of claim 23, wherein the subtherapeutically effective amount of dexamethasone is about 40 mg per week.
28. The use of any of claims 22 to 27, wherein dexamethasone is for administration once a day.
29. The use of any of claims 22 to 28, wherein dexamethasone is for administration for 4 days in a 28 day treatment cycle.
30. The use of claim 29, wherein dexamethasone is for daily administration on days 1, 8, 15, and 22 in the 28 day treatment cycle.
31. The use of any of claims 22 to 28, wherein dexamethasone is for administration for 12 days in a 28 day treatment cycle.
32. The use of claim 31, wherein dexamethasone is for daily administration on days 1 to 4, 9 to 12, and 17 to 20 in the 28 day treatment cycle.
33. The use of any of claims 22 to 32, wherein dexamethasone is for oral administration.
34. The use of any of claims 22 to 33, wherein the medicament is for administration of pomalidomide before dexamethasone.
35. The use of any of claims 22 to 33, wherein the medicament is for administration of pomalidomide concurrently with dexamethasone.
36. The use of any of claims 22 to 33, wherein the medicament is for administration of pomalidomide after dexamethasone.
37. The use of any of claims 1 to 36, wherein the medicament is for administration in combination with a third therapeutic agent.
38. The use of any of claims 1 to 37, wherein the subject has not been treated with anticancer therapy for the cancer prior to the administration of the medicament.
39. The use of any of claims 1 to 37, wherein the subject has been treated with anticancer therapy for the cancer prior to the administration of the medicament.

40. The use of claim 39, wherein the subject has been treated with at least two therapies for the cancer prior to the administration of the medicament.

41. The use of claim 39, wherein the subject has been treated with lenalidomide or bortezomib for the cancer prior to the administration of the medicament.

42. The use of claim 39, wherein the subject has been treated with lenalidomide and bortezomib for the cancer prior to the administration of the medicament.

43. Use of pomalidomide in the manufacture of a medicament for inhibiting the growth of a multiple myeloma cell, wherein the medicament is to contact with the cell in combination with a subtherapeutically effective amount of dexamethasone.

44. The use of claim 43, wherein the medicament is to contact the multiple myeloma cell before dexamethasone.

45. The use of claim 43, wherein the medicament is to contact the multiple myeloma cell concurrently with dexamethasone.

46. The use of claim 43, wherein the medicament is to contact the multiple myeloma cell after dexamethasone.